Regulatory T (TReg) cells provide tailor-made control of the immune response, according to new research by Alexander Rudensky and colleagues. Effector CD4+ T cells differentiate into functionally distinct T helper (TH) cell populations — TH1, TH2 and TH17 cells — depending on the environmental milieu; these same conditions are now shown to induce the differentiation of a corresponding TReg cell population to specifically regulate these TH cells.

The differentiation of TH17 cells involves the activation of signal transducer and activator of transcription 3 (STAT3). The authors found that phosphorylated (activated) STAT3 also has a function in TReg cells by binding forkhead box P3 (FOXP3), which is a crucial transcription factor for TReg cell development. Mice with a conditional deletion of Stat3 in only their TReg cells (Foxp3CreStat3fl/fl mice) developed splenomegaly and enlargement of the mesenteric lymph nodes draining the gastrointestinal tract by 6 weeks of age, which progressed to inflammatory bowel disease by 12–14 weeks of age. In contrast to the systemic lymphoproliferative disorder of TReg cell-deficient mice, pathology in Foxp3CreStat3fl/fl mice was limited to the intestinal mucosa, which indicates that only a subset of TReg cell functions are affected by deficiency of STAT3.

The Foxp3CreStat3fl/fl mice had more CD4+ effector T cells producing the TH17 cell cytokine interleukin-17 (IL-17) in the gut, whereas the production of TH1 and TH2 cell cytokines was similar in Foxp3CreStat3fl/fl and control mice. IL-17 production was shown to be the initial trigger for colitis induction in Foxp3CreStat3fl/fl mice. The co-transfer of STAT3-sufficient TReg cells completely abrogates the systemic, multi-organ autoimmunity that results from transfer of effector CD4+ T cells to immunodeficient mice. By contrast, the co-transfer of STAT3-deficient TReg cells with effector CD4+ T cells prevented systemic disease but resulted in an increased frequency of IL-17-producing CD4+ T cells in the gut and the development of colitis, which supports the selective dysregulation of TH17 cell responses in Foxp3CreStat3fl/fl mice.

These results show that STAT3 expression by TReg cells is required for the control of TH17 cell responses, and the authors suggest several possible mechanisms for this by comparing the expression patterns of FOXP3-dependent genes in STAT3-sufficient and -deficient TReg cells. First, STAT3 is required for the production of suppressor molecules such as IL-10 and IL-35 that are important for preventing colitis. Second, STAT3-dependent expression of the receptors for IL-1 and IL-6 could enable TReg cells to compete with TH17 cells for essential activation cues. Third, the expression of CC-chemokine receptor 6 by TReg cells, as well as TH17 cells, in a STAT3-dependent manner controls their migration to and therefore their spatial proximity in the gut. Finally, STAT3 activation in TReg cells inhibits the expression of soluble mediators of TH17 cell differentiation, such as transforming growth factor-β and vasoactive intestinal peptide.

So, this study not only confirms that TReg cells can directly suppress TH17 cell responses but also shows that transcription factors such as STAT3 can integrate environmental cues to provide 'class-specific' immune regulation.